KLOW Protocol
Four-Peptide Regenerative Blend | GHK-Cu + TB-500 + BPC-157 + KPV
On this page
What is KLOW Protocol?
KLOW is a four-peptide research blend — combining GHK-Cu, TB-500, BPC-157, and KPV in fixed ratios — built on the idea that peptides with different, complementary mechanisms might work together in tissue-repair research. Each individual peptide has its own research history, but no published studies have tested this specific four-peptide combination; the protocol remains investigational and its combined effects are theoretical. It's supplied here strictly as a research blend for laboratory study, not a proven or approved product.
Key terms:
KLOW Protocol is a multi-peptide combination protocol.
KLOW is a research peptide combination that builds on the GLOW protocol by adding KPV for stronger anti-inflammatory effects. This 80mg blend typically contains 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV — a 5:1:1:1 ratio. The individual components have varying levels of research support. No clinical trials have examined this specific four-peptide combination. The protocol remains investigational, with theoretical benefits based on complementary mechanisms.
Key research areas
- Theoretical synergistic effects from four peptides
- Tissue repair through multiple complementary pathways
- Anti-inflammation support
- Cellular regeneration potential
- Single injection convenience versus four separate peptides
Researched dosing
This table reflects the dosing ratios and schedules reported by vendors and research forums for this blend, presented as reference information, not personal usage instructions — no clinical trials have examined this specific combination.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Common study protocol | 3.2mg total (2mg GHK-Cu, 400mcg each TB500/KPV/BPC-157) | Once daily | Subcutaneous |
| Starting and step-up protocol | 2mg total (1.25mg GHK-Cu, 250mcg each TB500/KPV/BPC-157) | Once daily | Subcutaneous |
| Course-based protocol | As above | 4-6 weeks on, 2-4 weeks off | Subcutaneous |
Commonly cycled 6 weeks on, 2+ weeks off.
How it works
At the cell level, each of KLOW's four peptides is studied for a different mechanism — GHK-Cu for gene and collagen signaling, TB-500 for cell migration, BPC-157 for growth-factor pathways, and KPV for inflammation signaling — but no research has tested whether combining them changes how any of these mechanisms behave together.
Each peptide contributes different mechanisms: GHK-Cu modulates genes, TB-500 enhances cell migration, BPC-157 upregulates growth factors, KPV inhibits NF-κB
Research applications
This section lists the research areas — tissue repair, recovery, and inflammation — that the individual peptides in this blend have been studied for separately; it's a summary of component-level research, not evidence that this four-peptide combination itself has been studied, and not a claim about outcomes for any person.
Wound Healing
Addresses tissue repair through multiple complementary pathways. KPV may reduce injection site reactions compared to GLOW. Single injection versus four separate peptides provides convenience factor.
Recovery
Recovery support through combined mechanisms of individual peptide components including cell migration enhancement and growth factor upregulation.
Anti Inflammatory
Anti-inflammatory effects primarily through KPV's NF-κB inhibition and complementary mechanisms of other components.
Dosage reference
- Doses used in research
- 2–3.2 mg (0.1–0.16 mL at 20 mg/mL)
- Frequency in studies
- Once daily, typically evening
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- User reports vary - some claim benefits within days, others weeks
- Storage
- Must refrigerate after reconstitution
- Cycle length
- 4-6 weeks typical
- Break between cycles
- 2-4 weeks reported
Interactions
This list shows which other compounds are studied alongside KLOW's components, and flags combinations — including certain growth-hormone research compounds — that call for extra caution given how little is known about the combined blend.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried KLOW powder into a research solution — the same basic water-based mixing process used for most peptide-blend research.
- Clean vial top with alcohol pad
- Add 2-5mL bacteriostatic water (4mL creates 20mg/mL)
- Gently swirl - do not shake
- Solution should be clear to slightly cloudy
- Label with date and concentration
Lyophilized: 2-8°C, use within As per manufacturer; refrigerate
Reconstituted: 2-6°C, use within Use within 4-6 weeks
Open the KLOW Protocol reconstitution calculatorQuality indicators
These are the checks researchers use to confirm a KLOW sample came from a source that provides batch-specific third-party testing — since this is a four-component blend, verifying ratios and purity is especially important.
Third-party testing - Look for Janoshik or similar analytical verification
Reputable research supplier - Established vendors with quality control processes
Research-only status - Not approved for human use - research purposes only
Batch variability - Ratios and purity may vary between batches
No COA provided - Avoid vendors without certificates of analysis
What to expect
This timeline reflects what limited user-reported and component-level research suggests may occur — research context only, not a personal-results promise, since no formal studies exist for this specific combination.
Wound healing effects may take 2-4 weeks if they occur
Safety notes
This section covers handling cautions and regulatory notes for KLOW — no safety studies exist for the four-peptide combination, none of its components are FDA-approved for this use, and this entry is for research reference only, not medical guidance.
- No safety studies on four-peptide combination
- Long-term effects completely unknown
- Quality and contamination risks in unregulated market
- FDA has not approved any component for therapeutic use
- Individual peptides generally well-tolerated in research but combination is unstudied
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
GHK-Cu has extensive research showing wound healing, longevity, and gene modulation effects. However, these studies used GHK-Cu alone, not in combination.
One small pilot study showed 10 of 12 patients achieved complete resolution of interstitial cystitis symptoms with BPC-157. Most BPC-157 research remains in animal models.
No published studies on KLOW combination. Despite vendor claims and user reports, no scientific studies have examined the safety or efficacy of the four-peptide KLOW combination.